Fcpm Iii Services B.V. Makes New $25.68 Million Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Fcpm Iii Services B.V. acquired a new stake in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,872,537 shares of the biotechnology company's stock, valued at approximately $25,680,000. Astria Therapeutics accounts for about 4.4% of Fcpm Iii Services B.V.'s holdings, making the stock its 6th biggest position. Fcpm Iii Services B.V. owned 5.09% of Astria Therapeutics as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. KLP Kapitalforvaltning AS purchased a new position in shares of Astria Therapeutics during the fourth quarter worth $41,000. Tower Research Capital LLC TRC grew its holdings in shares of Astria Therapeutics by 109.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock worth $47,000 after buying an additional 2,766 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in Astria Therapeutics in the fourth quarter worth $50,000. Virtus ETF Advisers LLC purchased a new stake in shares of Astria Therapeutics during the 4th quarter worth approximately $65,000. Finally, Teacher Retirement System of Texas acquired a new stake in shares of Astria Therapeutics during the fourth quarter valued at $91,000. Institutional investors and hedge funds own 98.98% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on ATXS shares. HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Tuesday, March 11th. JMP Securities began coverage on Astria Therapeutics in a report on Friday, January 31st. They issued an "outperform" rating and a $26.00 price target on the stock. Citizens Jmp upgraded shares of Astria Therapeutics to a "strong-buy" rating in a report on Friday, January 31st. Cantor Fitzgerald reiterated an "overweight" rating and issued a $47.00 target price on shares of Astria Therapeutics in a report on Wednesday. Finally, Wedbush restated an "outperform" rating and issued a $28.00 target price (up previously from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $30.00.

Astria Therapeutics Stock Performance

Shares of ATXS stock traded down $0.01 on Wednesday, reaching $3.89. 334,306 shares of the company's stock traded hands, compared to its average volume of 365,542. Astria Therapeutics, Inc. has a 12-month low of $3.56 and a 12-month high of $12.92. The company has a market capitalization of $219.53 million, a P/E ratio of -1.86 and a beta of 0.45. The business's 50 day moving average price is $5.14 and its two-hundred day moving average price is $7.53.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.10). Research analysts predict that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.